Global hepatitis report The World Health Organization’s (WHO) Global Hepatitis Report is a comprehensive annual report providing an overview of the global burden of hepatitis, and a detailed assessment of prevention, screening, and treatment strategies and policies. The report provides evidence-based guidance to public health practitioners, policymakers, and health care providers to inform evidence-based approaches to tackling the burden of viral hepatitis. The report states that in 2018, 325 million people globally were chronically infected with viral hepatitis (B or C), and 1.4 million people worldwide died from viral hepatitis-related liver diseases due to a lack of access to effective prevention and treatment services. More than three-quarters of those deaths occurred in low- and middle-income countries. The global burden of viral hepatitis is estimated to be more than 20 times higher in 2020. The report outlines key findings on the burden of viral hepatitis, such as: • More than a third of the population globally is unaware of their infection status • Nearly 80% of individuals living with chronic hepatitis were not accessing life-saving treatment in 2018 • More than 80% of individuals with hepatitis B and 90% of individuals with hepatitis C acquired the virus through mother-to-child transmission, unsafe medical injections, and unsafe blood transfusions • Low- and middle-income countries experience 95% of the burden of viral hepatitis deaths The WHO identifies three main strategies to reduce the burden of viral hepatitis infections: i) increasing awareness, ii) expanding coverage of prevention and treatment. iii) strengthening health systems to provide better-integrated care for virus-infected individuals. https://www.magicinepharma.com/products/hepatitis-c

Sofosbuvir tablet a change in HCV treatment The treatment of Hepatitis C virus (HCV) has been revolutionised in the last decade with the introduction of oral direct-acting antivirals such as sofosbuvir tablets 400mg. These antiviral agents boast an impressive efficacy rate, with most patients clearing the HCV virus within 8-12 weeks of treatment. Furthermore, compared to previously used standard-of-care treatments such as pegylated interferon and ribavirin (which required 48-52 weeks of treatment and had variable efficacy rates), sofosbuvir is considered to be a remarkable leap forward in HCV therapy. Sofosbuvir tablets 400 mg is a nucleotide analogue that disables the HCV hepatitis enzymes responsible for HCV replication. It is taken orally in tablet form and requires no injections, making it convenient and less invasive than previous treatments. The sofosbuvir tablet generally provides 400mg per dose, administered twice daily. Generally, the recommended course of treatment is 12 weeks, but in certain circumstances, the duration of therapy may be altered. It is important to note that sofosbuvir should be taken in conjunction with other HCV antiviral agents, as sofosbuvir alone may not be enough to eradicate the virus. Common co-administered medications may vary among HCV genotypes and patient health conditions. What makes sofosbuvir tablets 400mg such an incredible breakthrough in HCV treatment is its convenient dosing regimen, a quick time period to effect, and reliable efficacy rate. https://www.magicinepharma.com/tablet/sofovir-sofosbuvir